NHS Framework for the North of England, Branded Medicine

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£432M
Sector
HEALTH
Published
01 Mar 2022
Delivery
01 Mar 2022 to 29 Feb 2024
Deadline
20 Oct 2021 13:00

Concepts

Location

Geochart for 1 buyers and 31 suppliers
NHS England
Thornton & Ross
Janssen Cilag
Biogen
Merck Serono
Celltrion Healthcare
Bristol Myers Squibb
Astrazeneca
Glaxosmithkline
Roche Products
Bayer
Novo Nordisk
Sandoz
Napp Pharmaceuticals
Eli Lilly
Teva
CST Pharma
Mylan
Gilead Sciences
Gedeon Richter
+−
Leaflet | Map tiles by Stamen Design, under CC BY 3.0. Data by OpenStreetMap, under ODbL.

1 buyer

31 suppliers

Description

Offer reference number: CM/PHR/20/5600 CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Award Detail

1 Thornton & Ross (Huddersfield)
  • Value: £238,913,892
2 Janssen Cilag (High Wycombe)
  • Value: £238,913,892
3 Biogen (Maidenhead)
  • Value: £238,913,892
4 Merck Serono (Feltham)
  • Value: £238,913,892
5 Celltrion Healthcare (Slough)
  • Value: £238,913,892
6 Bristol Myers Squibb (Uxbridge)
  • Value: £238,913,892
7 Astrazeneca (Luton)
  • Value: £238,913,892
8 Ul Global Pharma (None)
  • Value: £238,913,892
9 Glaxosmithkline (London)
  • Value: £238,913,892
10 Roche Products (Garden City)
  • Value: £238,913,892
11 Bayer (Reading)
  • Value: £238,913,892
12 Merck Sharpe & Dohme (London)
  • Value: £238,913,892
13 Pfizer (None)
  • Value: £238,913,892
14 Accord (None)
  • Value: £238,913,892
15 Novo Nordisk (Gatwick)
  • Value: £238,913,892
16 Sandoz (Camberley)
  • Value: £238,913,892
17 Napp Pharmaceuticals (Cambridge)
  • Value: £238,913,892
18 Eli Lilly (Basingstoke)
  • Value: £238,913,892
19 Ipsen (Slough)
  • Value: £238,913,892
20 Amgen (Cambridge)
  • Value: £238,913,892
21 Aventis Pharma (Reading)
  • Value: £238,913,892
22 Ucb Pharma (Slough)
  • Value: £238,913,892
23 Teva (Castleford)
  • Value: £238,913,892
24 Zentiva Pharma (London)
  • Value: £238,913,892
25 CST Pharma (Walsall)
  • Value: £238,913,892
26 Takeda (London)
  • Value: £238,913,892
27 Mylan (Barnet)
  • Value: £238,913,892
28 Gilead Sciences (Holborn)
  • Value: £238,913,892
29 Organon Pharmaceuticals (London)
  • Value: £238,913,892
30 Gedeon Richter (None)
  • Value: £238,913,892
31 Sobi Swedish Orphan Biovitrum (None)
  • Value: £238,913,892

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Reference

Domains